HRAS and head and neck cancer: Moreover, according to a curated set of non-redundant studies in cBioPortal, CASP8 and HRAS mutations, they seem to be generally more frequent in head and neck cancers (9.57% and 5.83%, respectively) than in gastroesophageal adenocarcinomas and squamous cell carcinomas (2.07% and 0.15%).